| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sisodia SS | |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 1169-1170 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Alzheimer's disease: perspectives for the new millennium | |
| P478 | volume | 104 |
| Q48422636 | Abeta peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease |
| Q37124928 | Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease |
| Q24633400 | Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients |
| Q33954737 | Amyloid-beta immunotherapy for Alzheimer's disease |
| Q40909568 | Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice |
| Q48087583 | ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo |
| Q35794590 | Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease |
| Q37346926 | Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters |
| Q33289360 | Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease |
| Q44754448 | Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion |
| Q37061721 | Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition |
| Q28504767 | Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease |
| Q30623665 | Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice |
| Q35596997 | Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease |
| Q28285644 | Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease |
| Q28240590 | Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics |
| Q42452241 | Cysteine proteases are the major β‐secretase in the regulated secretory pathway that provides most of the β‐amyloid in Alzheimer's disease: Role of BACE 1 in the constitutive secretory pathway |
| Q34777681 | Dementia epidemiology |
| Q53248698 | Effects of 60 Hz electromagnetic field exposure on APP695 transcription levels in differentiating human neuroblastoma cells. |
| Q28071703 | Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic |
| Q37880972 | Fish-on-a-chip: a sensitive detection microfluidic system for Alzheimer's disease |
| Q28247574 | Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein |
| Q38579624 | Genetic studies in Alzheimer's disease. |
| Q40632701 | HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration |
| Q44605297 | In VivoAssessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life |
| Q34155629 | Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 |
| Q39909606 | Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease? |
| Q94608446 | Kinetic analysis of aggregated amyloid-beta peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice |
| Q35748577 | Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. |
| Q30494949 | Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease |
| Q36556213 | Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation |
| Q90259725 | Notoginseng Saponin Rg1 Prevents Cognitive Impairment through Modulating APP Processing in Aβ1-42-injected Rats |
| Q36681098 | Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition. |
| Q38075593 | Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey |
| Q36488794 | Protease pathways in peptide neurotransmission and neurodegenerative diseases |
| Q35674780 | Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy |
| Q47815645 | Serum tumour necrosis factor-α and interleukin-6 levels in Alzheimer's disease and mild cognitive impairment |
| Q22252232 | Targeting TNF: a therapeutic strategy for Alzheimer's disease |
| Q28238581 | The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity |
| Q36331459 | Unawareness of deficits in Alzheimer's disease and other dementias: operational definitions and empirical findings |
| Q36642766 | Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease |
Search more.